NurExone Biologic (TSXV: NRX | OTCQB: NRXBF

- On August 12, 2026, NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) announced that its U.S. subsidiary Exo-Top Inc. had signed a binding memorandum of understanding with Made Scientific, Inc. to establish exclusive U.S. GMP manufacturing and commercial exosome supply.

- On August 18, six trading days after the announcement, NurExone shares moved sharply higher, closing roughly 20 percent up on the session.

The Announcement

Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization, or CDMO backed by GC Corporation, a global pharmaceutical group.. It operates a 60,000-square-foot U.S. FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey. Under the binding MOU announced by NurExone, Made Scientific becomes NurExone's exclusive U.S. partner for the manufacturing and aseptic fill-finish of NurExone's bone marrow-derived exosomes. Technology transfer begins immediately, in parallel with negotiation of a definitive agreement, and the parties are targeting first GMP exosome batches in the first half of 2027. The MOU contemplates a five-year initial term with options for successive five-year renewals.

CEO Dr. Lior Shaltiel framed the deal as a shift toward a specialized-partner manufacturing model. "Partnering with highly regarded organizations is essential to building world-class manufacturing around novel therapeutic approaches, including exosome-based therapies," Shaltiel said in the release. "Made Scientific is an ideal strategic partner because of its manufacturing capabilities, operational expertise, and shared long-term vision."

Why The Market Reacted

Preclinical biotech is one of the sectors where the market spends more time thinking about the science than about the plumbing behind it. Manufacturing is the plumbing. For an exosome company, it is also the wall almost every early-stage exosome program eventually runs into. GMP-grade production of biologics is difficult, capital-intensive, and heavily regulated. Companies that solve it tend to trade at a materially different multiple to those that have not.

Three specific things changed for NurExone on August 12.

A binding contract with a credentialed CDMO puts a real number on the manufacturing question. Made Scientific's Princeton facility is FDA- and EU GMP Annex 1-compliant. That is the class of facility regulators expect a therapy to come out of when it reaches human trials and commercial production. Prior to August 12, NurExone had a preclinical asset and a stated intent to build manufacturing capacity. As of August 12, the company has a binding MOU with a facility that already exists, already operates at the required regulatory grade, and is backed by a global pharmaceutical group.

NurExone has already done the work of showing its process can be repeatable. Now the manufacturing question moves to scale. Earlier this year, the company reported proteomic analysis showing strong consistency across four independent exosome production batches. The Novasign project added a structured bioprocess optimization initiative. The Made Scientific agreement represents the next logical step: transferring that process into an established U.S. GMP manufacturing environment designed to support larger-scale production.

The Made Scientific deal also builds on NurExone's earlier bioprocess optimization work with Novasign GmbH, announced on July 30, 2026. Together, the two partnerships now form the outline of a coherent manufacturing stack — process optimization on the front end, credentialed U.S. GMP production on the back — that was not visible in the story as recently as June.

What Comes Next

The near-term markers on the calendar are concrete: execution of the definitive agreement with Made Scientific, initiation of first GMP exosome batches in H1 2027, the IND submission itself, continued advancement of the large-scale preclinical optic nerve study at Sheba Medical Center, and first revenue from Exo-Top's naïve exosome sales business.

For a company whose story was previously anchored primarily in preclinical efficacy and regulatory designations, the addition of a credentialed U.S. GMP manufacturing partner on a defined calendar is the kind of structural change that resets the shape of the business. That reset is the mechanical explanation for the August 18 move.

The tickers are NRX on the TSX Venture Exchange, NRXBF on the U.S. OTCQB, and J90 on the Frankfurt Stock Exchange. For additional information, visit nurexone.com or public filings on SEDAR+.

Disclaimer: This content has been paid for by NurExone Biologic Inc. Cashu Group was compensated by NurExone Biologic Inc. for the creation and distribution of this content. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. The Made Scientific MOU referenced is a binding memorandum of understanding, not a completed definitive agreement. If the parties do not execute a definitive agreement within six months of MOU execution, the MOU and its exclusivity obligations automatically terminate. There is no guarantee a definitive agreement will be signed, that technology transfer will proceed on the anticipated timeline, or that first GMP exosome batches will be initiated in the target window. References to NurExone's Orphan Drug Designations, IND submission timing, ExoPTEN preclinical data, and past work by team members at other companies (including Pluristem, BrainStorm Cell Therapeutics, InnoCan Pharma, and Protalix Biotherapeutics) are historical or forward-looking as applicable and are not an indication of future performance at NurExone Biologic. Orphan Drug Designations provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. The August 18 share price movement referenced reflects publicly observable trading data on that date and is not a forward-looking statement about future price performance. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory approval. Readers should conduct their own due diligence, consult NurExone's public filings on SEDAR+, and consult with a qualified financial advisor before making any investment decisions.